Results 11 to 20 of about 30,219 (216)

Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment

open access: yesCells, 2022
Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arrest and repair treatment-induced DNA damage.
Mathew Lozinski   +6 more
doaj   +1 more source

DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma

open access: yesFrontiers in Immunology, 2022
BackgroundDNA damage response (DDR) proficiency is the principal mechanism of temozolomide (TMZ) resistance in glioma. Accumulating evidence has also suggested the determining role of DDR in anticancer immunity.
Mu Chen   +12 more
doaj   +1 more source

COP9 signalosome function in the DDR [PDF]

open access: yesFEBS Letters, 2011
The COP9 signalosome (CSN) is a platform for protein communication in eukaryotic cells. It has an intrinsic metalloprotease that removes the ubiquitin (Ub)‐like protein Nedd8 from cullins. CSN‐mediated deneddylation regulates culling‐RING Ub ligases (CRLs) and controls ubiquitination of proteins involved in DNA damage response (DDR).
Hannß, Ronny, Dubiel, Wolfgang
openaire   +2 more sources

Monitoring the Activation of the DNA Damage Response Pathway in a 3D Spheroid Model. [PDF]

open access: yesPLoS ONE, 2015
Monitoring the DNA-Damage Response (DDR) activated pathway in multicellular tumor spheroid models is an important challenge as these 3D models have demonstrated their major relevance in pharmacological evaluation.
Odile Mondesert   +5 more
doaj   +1 more source

DNA damage response signaling: A common link between cancer and cardiovascular diseases

open access: yesCancer Medicine, 2023
DNA damage response (DDR) signaling ensures genomic and proteomic homeostasis to maintain a healthy genome. Dysregulation either in the form of down‐ or upregulation in the DDR pathways correlates with various pathophysiological states, including cancer ...
Sepideh Nikfarjam, Krishna K. Singh
doaj   +1 more source

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors

open access: yesFrontiers in Oncology, 2021
BackgroundDNA damage repair (DDR) genes were recently implicated in the anti-tumor immune response. Therefore, it is worthwhile to unravel the implications of DDR pathways in the shaping of immune responsiveness in colorectal cancer (CRC) patients ...
Yipeng Song   +12 more
doaj   +1 more source

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

open access: yesFrontiers in Oncology, 2021
DNA damage repair (DDR) pathways play an essential role in maintaining genomic integrity. DDR dysfunction leads to accumulated DNA damage, predisposition to cancer, and high sensitivity to chemotherapy and radiotherapy.
Wei Sun   +5 more
doaj   +1 more source

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

open access: yesJournal for ImmunoTherapy of Cancer, 2020
Background Loss-of-function alterations in DNA damage repair (DDR) genes are associated with human tumorigenesis and may determine benefit from immune-oncology (I/O) agents as shown in colon cancer.
Andrea Knezevic   +15 more
doaj   +1 more source

Dynamic differences between DNA damage repair responses in primary tumors and cell lines

open access: yesTranslational Oncology, 2021
The study of DNA damage repair response (DDR) in prostate cancer is restricted by the limited number of prostate cancer cell lines and lack of surrogates for heterogeneity in clinical samples.
Collin Gilbreath   +11 more
doaj   +1 more source

The DDR is in [PDF]

open access: yesScience-Business eXchange, 2011
An international team looking to target subsets of squamous cell lung cancer has identified mutations in DDR2 that drive 3%–4% of cases. The researchers are aiming to start a Phase II trial with Bristol-Myers's Sprycel, a marketed kinase inhibitor that blocks DDR2.
openaire   +1 more source

Home - About - Disclaimer - Privacy